Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pan-KRAS inhibitor BGB-53038

An orally bioavailable inhibitor of KRAS mutations, with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor BGB-53038 selectively targets, binds to and inhibits various forms of KRAS mutations, thereby inhibiting KRAS-dependent signaling. This inhibits the proliferation of and induces apoptosis in tumor cells in which KRAS is mutated. KRAS, a member of the RAS family of oncogenes, plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis. BGB-53038 has only weak inhibitory activity against NRAS and HRAS, which may reduce the risk of side effects.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:KRAS inhibitor BGB-53038
KRAS mutant-selective inhibitor BGB-53038
pan-KRAS mutant inhibitor BGB-53038
Code name:BGB 53038
BGB-53038
BGB53038
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search